GW Pharmaceuticals, PLC (GWPH)

gwpharma-logoGW Pharmaceuticals, PLC is a biopharmaceutical company based in United Kingdom, and is engaged in the research, manufacture, and commercialization of cannabinoid-based prescription medicines that contain controlled substances, and plant-based pharmaceutical products to meet the needs of patients in a range of therapeutic conditions. The company maintains in-house control over all aspects of the development process of their cannabinoid products, such as botanical research, extraction technology, drug formulation, clinical trials, and regulatory affairs.

Founded in 1998, GW Pharmaceuticals, PLC has become a world leader in cannabinoid science. The company has developed an international network of the field’s most prominent scientists. In 2007, the collaboration of GW and Otsuka paved the way for the significant expansion of the early cannabinoid research activities of GW. Both companies have collaborated in researching novel cannabinoids as potential treatments for central nervous system disorders. GW also has an in-house program that researches cannabinoids as treatments for Type 2 diabetes and related metabolic disorders.

The lead product of GW Pharmaceuticals, PLC is Sativex, which has been either approved for use or recommended for approval in 24 countries. Sativex is a treatment for symptom improvement in patients suffering from moderate to severe spasticity brought about by Multiple Sclerosis.

Sativex is currently in Phase III clinical development for cancer pain treatment. To provide patients from different countries with easy access to Sativex, the company has entered into separate licensing agreements with Almirall in Mexico and Europe; Bayer Healthcare in Canada and the UK; Otsuka Pharmaceutical in the U.S.; Novartis in Africa, Asia and the Middle East; and Neopharm in Israel.

GW Pharmaceuticals, PLC is listed under the symbol GWPH on the NASDAQ Global Market, as well as on AIM, a market of the London Stock Exchange. The company is licensed to work with controlled substances for medical research purposes. The company continues to focus on developing a product portfolio of cannabinoid-based prescription medicines, including Epidiolex and Sativex Oromucosal Spray, to meet the needs of patients in a wide range of medical indications.


Yahoo! Finance: GWPH News

Latest Financial News for GWPH

Five things you should know about Stephen Hahn, the new FDA commissioner

The Senate on Thursday afternoon confirmed Dr. Stephen Hahn, a radiation oncologist, as the new head of the Food and Drug Administration.

Cramer Advises His Viewers On GW Pharma, Enphase And More

On CNBC's "Mad Money Lightning Round," Jim Cramer said GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) is a long-term hold. Zuora Inc (NYSE: ZUO ) is in the penalty box for Cramer because it hasn't ...

Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

CARLSBAD, Calif., Dec. 07, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription.

GW Pharmaceuticals (NASDAQ:GWPH) Shareholders Have Enjoyed A 43% Share Price Gain

GW Pharmaceuticals plc (NASDAQ:GWPH) shareholders might be concerned after seeing the share price drop 26% in the last...

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

LONDON and CARLSBAD, Calif., Dec. 05, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid.